Environmental

IRWD’s high R&D intensity supports a lower-emissions innovation profile versus peers, because a larger share of spend is directed toward science rather than manufacturing scale.

The company’s asset-light operating model likely reduces direct environmental footprint relative to peers with heavier production and logistics exposure, limiting Scope 1 and 2 intensity.

No disclosed environmental controversies or material compliance issues were provided, which leaves IRWD’s environmental profile broadly in line with better-positioned specialty biopharma peers.

Environmental execution remains less visible than at top-tier peers with explicit decarbonization targets and detailed sustainability reporting, which caps relative strength.

Social

IRWD’s R&D-heavy model can support patient-benefit innovation, because social value is tied to therapies addressing unmet medical needs rather than commoditized products.

The company’s low stock-based compensation as a share of revenue suggests comparatively restrained dilution pressure, which can align management incentives more closely with long-term stakeholder interests than peers.

No major labor, product-safety, or access-to-medicine controversies were provided, so IRWD appears socially steadier than peers facing recurring compliance or affordability disputes.

As a smaller biopharma company, IRWD likely has less community and workforce scale than larger peers, which can limit the breadth of its social programs and disclosure.

Governance

IRWD’s very high gross margin indicates strong product economics, but governance assessment depends more on oversight quality than operating leverage, so the metric is only indirectly supportive.

R&D spending at roughly 22.5% of revenue suggests disciplined capital allocation toward pipeline development, which is favorable versus peers that underinvest in innovation.

Stock-based compensation at about 5.8% of revenue is manageable, but it still implies meaningful equity dilution risk relative to peers with tighter compensation discipline.

The negative debt-to-equity reading limits comparability, and without filing-based board, audit, and ownership detail, IRWD’s governance profile remains less transparent than best-in-class peers.

Overall Score

IRWD screens as a strong relative ESG performer versus peers, led by an innovation-oriented operating model and generally restrained social and environmental risk exposure.

Score Driver: High R&D Intensity With Limited Disclosed ESG Controversies